Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2023 Earnings Conference Call April 27, 2023 8:30 AM ET

Company Participants

Louise Wilkie - VP, IR and Corporate Communications

Alexander D. Macrae - President and CEO

D. Mark McClung - EVP and COO

Prathyusha Duraibabu - SVP, Principal Accounting Officer and CFO

Jason D. Fontenot - SVP and Chief Scientific Officer

Nathalie Dubois-Stringfellow - SVP and Chief Development Officer

Bettina M. Cockroft - CMO

Conference Call Participants

Benjamin Burnett - Stifel

Gregory Harrison - Bank of America

Gena Wang - Barclays

Maury Raycroft - Jefferies

Yanan Zhu - Wells Fargo

Unidentified Analyst - RBC Capital Markets

Patrick Trucchio - H.C. Wainwrigt

Operator

Good day and thank you for standing by. Welcome to the Sangamo First Quarter 2023 Teleconference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions]. Please be advised that today’s conference is being recorded. I would now like to hand the conference over to your speaker today Louise Wilkie. Please go ahead.

Louise Wilkie

Thank you. Good morning. I'm Louise Wilkie, Sangamo's Vice President of Investor Relations and Corporate Communications. Thank you for joining us on the call today. On this call are several members of Sangamo executive leadership team, including Sandy Macrae, Chief Executive Officer; Mark McClung, Chief Operating Officer; Prathyusha Duraibabu, Chief Financial Officer; Jason Fontenot, Chief Scientific Officer; Nathalie Dubois-Stringfellow, Chief Development Officer; and Bettina Cockroft, Chief Medical Officer. Slides from our corporate presentation can be found at our Website, sangamo.com under the Investors & Media section on the Events and Presentations page.

This call includes forward-looking statements regarding Sangamo's current expectations. These statements include, but are not limited to, statements relating to the therapeutic and commercial potential of our product candidates, the anticipated plans and time lines of Sangamo and our collaborators for initiating and conducting clinical trials, screening, and dosing patients and presenting clinical data, advancements of our product candidates, advancements of preclinical programs to the clinic, our strategic reprioritization and restructuring and the anticipated benefits thereof. The sufficiency of our resources, cash runway, and plans to seek additional capital, our preliminary estimated operating results for quarter-ended March 31, 2023, estimated financial guidance and targets for 2023 and beyond, upcoming catalysts and milestones, and other statements that are not historical facts.

Actual results may differ materially from what we discussed today. These statements are subject to certain risks and uncertainties that are discussed in our filings with the SEC specifically on our annual report on Form 10-K for the fiscal year ended December 31, 2022 as supplemented by our quarterly report on Form 10-Q for the quarter ended March 31, 2023 to be filed with the SEC. The forward-looking statements stated today are made as of this date, and we undertake no duty to update such information, except as required by law. On this call, we discuss our non-GAAP operating expenses. Reconciliation of this measure to our GAAP operating expenses can be found in our press release, which is available on our website.